BioSpace News Archive

IRLAB Therapeutics AB held its Annual General Meeting at Wallenbergs Konferenscentrum, Medicinaregatan 20 A in Gothenburg, Sweden.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance Treg function, today announced expansion of its patent estate for COYA 301, the Company’s low-dose IL-2 (ld IL-2) subcutaneous administration product candidate.

Abcam plc, a global leader in the supply of life science research tools, filed an investor presentation with the U.S. Securities and Exchange Commission in connection with the Extraordinary General Meeting of the Company to be held on July 12, 2023 at 2:00pm || 9:00am.

Oramed Pharmaceuticals Inc. announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association’s 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California.

PDS Biotechnology Corp. announced its expected addition to the broad-market Russell 2000® and the Russell 3000® Indexes in accordance with the 2023 Russell indexes annual reconstitution.

Harvard Bioscience, Inc. announced the appointment of Jennifer Cote as the Company’s Chief Financial Officer and Treasurer, effective June 19, 2023.

Predictive Oncology Inc., a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments laboratory and Good Manufacturing Practices facility, to accelerate oncology drug discovery and enable drug development, announced the appointment of Dr. Bernard A. Harris, Jr. to its newly-formed Business Advisory Board.

TRACON Pharmaceuticals (NASDAQ: TCON) today announced the positive results of a six-month independent data monitoring committee (IDMC) review for the ongoing ENVASARC Phase 2 pivotal trial.

ARS Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration extended the Prescription Drug User Fee Act target action date by three months for the New Drug Application for neffy Epinephrine) for the treatment of allergic reactions, including anaphylaxis, for adults and children ≥30 kg.